

Strathclyde minor groove binders (S-MGBs) with activity against *Acanthamoeba castellanii*

Leah M. C. Mcgee¹, Alemao G. Carpinteyro Sanchez², Marina Perieteanu¹, Kaveh Eskandari¹, Yan Bian¹, Logan Mackie², Louise Young², Rebecca Beveridge¹, Colin J. Suckling¹, Craig W. Roberts² and Fraser J. Scott^{1*}

¹Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow, UK; ²Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK

*Corresponding author. E-mail: fraser.j.scott@strath.ac.uk

Received 22 October 2023; accepted 15 June 2024

Background: *Acanthamoeba* spp. is the causative agent of *Acanthamoeba* keratitis and granulomatous amoebic encephalitis. Strathclyde minor groove binders (S-MGBs) are a promising new class of anti-infective agent that have been shown to be effective against many infectious organisms.

Objectives: To synthesize and evaluate the anti-*Acanthamoeba* activity of a panel of S-MGBs, and therefore determine the potential of this class for further development.

Methods: A panel of 12 S-MGBs was synthesized and anti-*Acanthamoeba* activity was determined using an alamarBlue™-based trophocidal assay against *Acanthamoeba castellanii*. Cross-screening against *Trypanosoma brucei brucei*, *Staphylococcus aureus* and *Escherichia coli* was used to investigate selective potency. Cytotoxicity against HEK293 cells allowed for selective toxicity to be measured. DNA binding studies were carried out using native mass spectrometry and DNA thermal shift assays.

Results and discussion: S-MGB-241 has an IC₅₀ of 6.6 µM against *A. castellanii*, comparable to the clinically used miltefosine (5.6 µM) and negligible activity against the other organisms. It was also found to have an IC₅₀ > 100 µM against HEK293 cells, demonstrating low cytotoxicity. S-MGB-241 binds to DNA as a dimer, albeit weakly compared to other S-MGBs previously studied. This was confirmed by DNA thermal shift assay with a $\Delta T_m = 1 \pm 0.1^\circ\text{C}$.

Conclusions: Together, these data provide confidence that S-MGBs can be further optimized to generate new, potent treatments for *Acanthamoeba* spp. infections. In particular, S-MGB-241, has been identified as a ‘hit’ compound that is selectively active against *A. castellanii*, providing a starting point from which to begin optimization of DNA binding and potency.

Introduction

Acanthamoeba spp. are among the most prevalent free-living amoebae, occurring in many natural environments, but also thrive in man-made habitats.¹ This amoeba is amphizoic being able to feed on bacteria, algae and yeasts, but importantly is also a facultative and opportunistic parasite of humans. It can live under extreme conditions concerning pH, level of oxygen, salinity and temperature. The life cycle of *Acanthamoeba* comprises two stages: an infective trophozoite stage that feeds and multiplies, and a dormant resistant cyst stage, which allows the amoeba not only to withstand harsh conditions, but also resist disinfection in the environment and drug therapy when parasitic.²

As a facultative parasite, *Acanthamoeba* spp. is the causative agent of a painful sight-threatening infection known as

Acanthamoeba keratitis (AK) occurring mostly in contact lens wearers.³ Granulomatous amoebic encephalitis (GAE), is a result of opportunistic infection in immunodeficient patients and is almost always fatal. It is sometimes associated with disseminated infection that typically shows as skin infection or inflammation of the lungs and sinuses.⁴ Despite low incidence, patients infected with AK experience severe morbidity, which can be compounded by late diagnosis. Successful treatment of GAE is rare, but options used include treatment of underlying immunodeficiency, or a combination of chemotherapy, surgery and cryotherapy.^{5,6} Cases of AK are increasing due to a lack of awareness in the clinic, the deficiency of rapid diagnostic tools and increased numbers of people wearing contact lenses.⁷ Current therapies for AK are arduous as they require the repeated topical application of drugs to the cornea. In the UK, a combination of biguanide (PHMB or




Figure 1. Structures of minor groove binders. (a) MGBs which interact with DNA via non-covalent interactions diminazene, **1**, and distamycin, **2**. (b) alkylating MGBs tallimustine, **3**, and brostallicin, **4**. (c) MGBs with anti-acanthamoeba properties, MGB6, **5**, MGB16, **6** and MGB22, **7**, as reported by Alniss et al.¹⁰ This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.

Chlorhexidine) and a diamidine (propamidine or hexamidine) are administered hourly day and night for the first 48 hours; this is continued hourly during daytime only for 2 weeks and then every 2 hours for at least 3–4 weeks.⁸ More recently, for disease that is unresponsive, miltefosine has been administered orally as an adjuvant systemic therapy.⁹ Even this does not reliably result in medical cure and can leave the cornea sufficiently damaged to require a keratoplasty. Thus, there is an urgent need to create new improved compounds to treat these diseases and avoid the worst patient outcomes.

Minor groove binders (MGBs) are small molecules that bind to the minor groove of DNA and consequently interrupt various DNA-centric processes. There are several structural classes of MGB, including the anti-parasitic diamidines, such as diminazene, **1**, a treatment for animal African trypanosomiasis, and also derivatives of the natural product distamycin, **2**. These compounds typically interact with the minor groove of DNA through non-covalent interactions and thus are able to bind reversibly without damaging DNA. However, several anti-cancer MGBs do contain an alkylating moiety, such as tallimustine, **3**, or brostallicin, **4**, which imparts additional safety concerns that are not relevant for non-alkylating MGBs (Figure 1).

The Strathclyde MGB (S-MGB) drug discovery platform is based on the template of distamycin, **2**. Over many iterations, the structure has been optimized to yield compounds with various

anti-infective properties, including anti-parasitic, anti-viral, anti-bacterial, anti-mycobacterial and anti-fungal.^{10–13} Like distamycin, S-MGBs are able to bind to AT-rich sequences of DNA, enabling these compounds to target multiple loci on a pathogen's DNA.¹⁴ Thus, S-MGBs fully embrace the multitargeted anti-infective drug concept, advantageous in this antimicrobial resistance era due to the reliance to target-based resistance it brings.¹⁵ Indeed, several studies have confirmed that S-MGBs are resilient to the generation of resistance in laboratory experiments.¹⁶ Our continued interest in expanding the clinical potential of S-MGBs lead us to investigate their effects against the amoeba *A. castellanii*.

In parallel with our present studies, Alniss et al. have also investigated and disclosed distamycin derived MGBs with anti-*Acanthamoeba* properties (Figure 1c).¹⁷ 12 structurally diverse MGBs were synthesized that explored the significance of features such as head group lipophilicity, tail group basicity and heterocycle substitutions. The MGBs' amoebicidal activity and effects on encystation and excystation were studied. Amoeba-mediated host-cell death was also investigated through cytopathogenicity assays. Ultimately, their MGB6, **5**, MGB16, **6**, and MGB22, **7**, were found to be most potent in their assays cascade, noting that MGB6, **5**, had the most potent IC₅₀ of 58 μM in the amoebicidal assay.

In our study, 12 S-MGBs, including zwitterionic structures, were synthesized and evaluated for activity against several pathogens, including *Acanthamoeba castellanii*, *Trypanosoma brucei*,

Staphylococcus aureus and *Escherichia coli*. Zwitterionic structures were of interest as they have not been explored in our extensive studies on S-MGB structure activity relationships. Additionally, the compounds in this set adopt our recent truncated S-MGB strategy, shortening the overall length of the molecules, which has previously shown to result in selectivity towards the parasitic organisms, including *Trypanosoma* spp. and *Leishmania* spp., over other bacterial pathogens, *S. aureus* and *E. coli*.¹⁸ A zwitterionic S-MGB, S-MGB-241, **36**, was discovered that is selectively potent against *A. castellanii* with an IC₅₀ of 6.6 µM in a trophocidal assay, and non-cytotoxic (IC₅₀ > 100 µM) against HEK293 cells.

S-MGB-241, **36**, has been shown to stabilize gDNA using a thermal shift assay, and also bind to a short AT-rich dsDNA oligomer using native mass spectrometry, albeit weakly in both cases. This is in line with the lower relative potency of S-MGB-241, **36**, compared to other S-MGBs that are effective against different pathogens and have concomitantly greater DNA binding. However, a different mechanism of action not involving DNA cannot be ruled out entirely.

Methods

Anti-acanthamoeba trophocidal assay

The *Acanthamoeba castellanii* Neff strain was donated by Keith Vickerman. The microtiter plate alamarBlue™, resazurin assay was carried out as previously described.¹⁹ The compounds were tested over a range of 10-fold dilution concentrations in triplicate against *Acanthamoeba castellanii* (4 × 10⁴ seeding density), then the plates were incubated at 23°C for 96 hours. Six hours before the end of the incubation period, 10 µL of alamarBlue™ reagent (BioRad, UK) was aseptically added to all the wells except the blank. Afterwards, the plate was incubated for 6 hours at 23°C in dark conditions. Controls were included in each plate, consisting of PG blank, trophozoites with medium alone, trophozoites with the highest concentration of solvent (DMSO), PG medium with the highest concentration of S-MGB alone and PG medium alone with alamarBlue. The final volume for all wells was 100 µL. Finally, the absorbance was then read on a Spectromax (Molecular Devices, USA) spectrophotometer at OD570 and OD600.

Antibacterial assay

The MIC against *S. aureus* ATCC 43300 and *E. faecalis* ATCC 51299 was measured by making two-fold serial dilutions of the samples into a 96-well non-binding surface plate (Corning #3640). Bacteria were cultured in CAMHB overnight at 37°C, diluted 40-fold and incubated for a further 1.5–3 h at 37°C. The resultant mid-log phase cultures were diluted and added to each well of the compound containing plates, giving a cell density of 5 × 10⁵ cfu/mL, measured by absorbance at 600 nm (OD₆₀₀) and a final compound concentration range of 50–0.0195 µM. All plates were covered and incubated at 37°C for 18 h without shaking. Inhibition of bacterial growth was determined by OD₆₀₀, using a Tecan Infinite M Nano plate reader. The percentage of growth inhibition was calculated for each well, correcting for background using a negative control (medium only) and a positive control (bacteria without inhibitors) on the same plate. The MIC was determined as the lowest concentration at which the growth was fully inhibited, defined by an inhibition 80%. Each MIC determination was carried out in triplicate on separate days.

Anti-*Trypanosoma* assay

Bloodstream form *T. b. brucei* (Lister 427) was cultured in HMI-11 medium (Gibco) supplemented with 10% heat inactivated FBS (Gibco), at 37°C in a humidified 5% CO₂ environment. EC₅₀ values against

T. b. brucei were determined by an *in vitro* alamarBlue™ assay. *T. b. brucei* parasites (2 × 10⁴ cells per mL) were seeded into serial dilutions of the test compounds to a final volume of 200 µL and incubated for 48 h, after which 20 µL of 0.49 mM resazurin dye (Sigma-Aldrich) was added and cells were incubated for a further 24 h. The reduction of resazurin was measured using a fluorimeter (FLUOstar Optima, BMG Labtech) at 544 nm excitation and 590 nm emission wavelengths. MIC values were identified as the minimum concentration required to inhibit 80% of growth. All experiments were carried out on at least three independent occasions.

HEK293 cytotoxicity

Human embryonic kidney cells (HEK293) were obtained from Sigma-Aldrich, UK. The cells were seeded in 75 cm² vented flasks at a concentration of 1.5 × 10⁴ cells/well in DMEM, pH 7.4, and grown in a humidified incubator at 37°C in the presence of 5% CO₂. The DMEM was supplemented with 10% FBS, 1% penicillin/streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate and either galactose (4.5 g/L) or glucose (4.5 g/L) (all consumables Sigma-Aldrich, UK). Cells were grown to 80% confluence and passaged using 1X TrypLe™ express enzyme (Thermo Fisher Scientific, UK)

For viability determination, HEK293 cells were seeded at a concentration of 1500 cells/well (50 µL) in black 96-well half-area clear bottomed plates (Greiner, UK). Cells were allowed to attach overnight then were exposed to a final concentration of 12.5, 25, 50 and 100 µM S-MGB-241 in a total volume of 60 µL per well (stock S-MGB-241 was dissolved in DMSO at a concentration of 10 mM). Cells in the absence of compound were termed control wells and represented 100% viability. Complete kill was determined by the addition of 0.1% Triton X. Cell viability was assessed after 24 hours of incubation at 37°C (humidified, 5% CO₂) using 10% v/v PrestoBlue™ HS Cell Viability reagent (Sigma-Aldrich, UK) according to manufacturer's instructions. The resulting reduction of this resazurin dye (Presto Blue™) was quantified using a Hidex Sense multimode plate reader (Lablogic, UK and Ireland) in fluorescent mode with excitation and emission wavelengths of 535/20 and 595/10 nm, respectively.

The viability of the treated samples was expressed as a percentage of the control wells containing DMSO (vehicle). Statistical analysis was performed using the mean ± standard error (SE) values derived from three independent experiments.

Data were plotted using Graph Pad Prism Software: Graph Pad Prism version 9.00 for Windows (GraphPad Software, La Jolla CA, USA: www.graphpad.com)

UV-vis DNA thermal melting experiments

Salmon genomic DNA (gDNA; D1626, Sigma-Aldrich) at 1 mg/mL in 1 mM phosphate buffer (pH 7.4) containing 0.27 mM KCl and 13.7 mM NaCl (P4417, Sigma-Aldrich) was annealed at 90°C for 10 min and left to cool to room temperature. S-MGBs at 10 mM in DMSO were diluted with the same phosphate buffer to yield a single sample with 10 µM S-MGB and 0.02 mg/mL gDNA in 1 mM phosphate buffer containing 0.27 mM KCl and 13.7 mM NaCl. Control samples containing only S-MGB or gDNA were prepared, respectively. Samples were melted at a rate of 0.5°C/min from 45 to 90°C with spectra recorded at 260 nm on a UV-1900 UV-vis spectrophotometer fitted with a Peltier temperature controller (Shimadzu) using LabSolutions (Tm Analysis) software. The melting temperatures (T_ms) of the S-MGB:DNA complexes were determined by fitting a sigmoidal function using a Boltzmann distribution in OriginPro.

Native mass spectrometry

For DNA sample preparation, DNA oligonucleotide sequence 5'-CGCATATATGCG-3' was purchased in lyophilized form from Alpha DNA (Canada) and used without further purification, purity assessed by NMR. Then 100 µM stock solutions of DNA were prepared with 150 mM ammonium

acetate solution (Fisher Scientific, Loughborough, Leicestershire, UK) and 2 mM potassium chloride solution (Fisher Scientific, Loughborough, Leicestershire, UK). This solution was annealed at 90°C for 10 minutes and allowed to cool to room temperature. Next, 10 mM S-MGB stock in 100% DMSO (Sigma-Aldrich, St Louis, MO, USA) were diluted to 1 mM S-MGB solution with 150 mM ammonium acetate. Final samples were prepared from this solution to yield final concentrations of 9 µM DNA, 100 µM KCl and 100 µM s-MGB, 1% DMSO. DNA solutions containing no S-MGB included 1% DMSO and were used as controls.

When taking the mass spectrometry measurements, native mass spectrometry experiments were carried out on a Synapt G2Si instrument (Waters, Manchester, UK) with a nano electrospray ionization source (nESI). Mass calibration was performed by a separate infusion of NaI cluster ions. Solutions were ionized from a thin-walled borosilicate glass capillary (i.d. 0.78 mm, o.d. 1.0 mm, Sutter Instrument Co., Novato, CA, USA) pulled in-house to nESI tip with a Flaming/Brown micropipette puller (Sutter Instrument Co., Novato, CA, USA). A negative potential in range of 1.0–1.2 kV was applied to the solution via a thin platinum wire (diameter 0.125 mm, Goodfellow, Huntingdon, UK). The following non-default instrument parameters were used for the DNA: S-MGB-241 complex: capillary voltage 1.4 kV, sample cone voltage 100 V, source offset 110 V, source temperature 40°C, trap collision energy 3.0 (V), trap gas 3 mL/min. For DNA with no MGB present, the following parameters were changed: capillary voltage 1.0 kV, sample cone voltage 80 V, source offset 95 V and trap gas 4.0 mL/min. Data were processed using Masslynx v.4.2 and OriginPro v.2021, and figures were produced using ChemDraw.

Results and discussion

Chemistry

A panel of 12 S-MGBs was synthesized to investigate the biological activity of zwitterionic S-MGBs. The methodology associated with the synthesis can be found in the Supplementary Information. The S-MGBs were constructed from previously synthesized dimers **22**, **23** and **24** (Figure 2).^{20,21} Briefly, an HBTU-mediated amide coupling of the appropriate amine (**9**, **10** or **11**) with nitro pyrrole carboxylic acid, **8**, provided **12**, **13** and **14**. This was followed by hydrogenation of the nitro group to an amine, followed directly by another HBTU-mediated coupling with nitro pyrrole carboxylic acid, **8**, to yield nitro dimers **18**, **19** and **20**. A Pinner reaction of nitro dimer **20** provided access to amidine dimer **21**. Methyl ester containing S-MGBs **27–32**, were obtained through an HBTU-mediated amide coupling of carboxylic acids **25** or **26** with the appropriate amino dimers **22–24**, which were in turn obtained via hydrogenation using Pd/C from the corresponding nitro compounds (**18**, **19** and **21**). All methyl ester compounds were subsequently hydrolysed using lithium hydroxide to obtain the corresponding zwitterionic S-MGBs **33–38** in moderate yields (51%–68%) and >95% purity.

Biological evaluation

The set of 12 S-MGBs was evaluated against *Acanthamoeba castellanii* (Neff strain) as an indication of anti-amoeba activity, with miltefosine as a positive control. Additionally, the compounds were screened against *Trypanosoma brucei brucei* (Lister 427), *Staphylococcus aureus* (ATCC 43300) and *Escherichia coli* (ATCC 25922) (Table 1). Dose–response curves against *Acanthamoeba castellanii* (Neff strain) can be found in the Supplementary Information (Figure S1, available as [Supplementary data](#) at JAC Online).

S-MGB-241, **36**, is the most active compound against *A. castellanii* (IC₅₀ of 6.6 µM), and the most selective to this organism over the others tested. The zwitterionic nature of this S-MGB, and thus lower logP, may be significant in the observed potency towards *Acanthamoeba castellanii*, as a comparison of S-MGB-241, **36**, with its methyl ester analogue, S-MGB-238, **30**, reveals the latter to have no measurable activity against *A. castellanii*. However, a pair-wise comparison across all carboxylic acid and methyl ester pairs does not consistently maintain this trend, which suggests that logP and the zwitter ionic nature are not sufficient explanatory factors. It is also possible that there is a confounding effect from the tail group. Indeed, there does not appear to be an obvious trend when considering only the basicity of the tail group either as the dimethyl amino tail, with intermediate basicity, led to the most active compound, **36**. None-the-less, S-MGB-241, **36**, is the first zwitterionic S-MGB with notable antimicrobial activity that has been identified from the S-MGB platform.

S-MGB-227, **31**, exhibits moderate potency for *A. castellanii* (IC₅₀ of 18.01 µM), and activity against *Trypanosoma brucei* (MIC 3.12 µM). The amidine containing analogue of S-MGB-227, **31**, S-MGB-233, **32**, also exhibited moderate activity towards *Trypanosoma brucei*, but was less potent than its morpholine analogue against both parasites. None of the compounds were found to have measurable activity against either of the bacterial strains, *E. coli* or *S. aureus*.

The cytotoxicity of S-MGB-241, **36**, was evaluated against HEK293 cells, using both galactose and glucose supplementation. S-MGB-241, **36**, was determined to have an IC₅₀ > 100 µM (Figure S2) in both cytotoxicity models, providing a satisfactory selectivity index (>15).

The kinetics of S-MGB-241 inhibition of *A. castellanii* was further investigated by truncating treatment duration to 24 h. S-MGB was found to inhibit AlmarBlue reduction by *Acanthamoeba* in a dose dependent manner with maximal effect noted at concentrations above 50 µM (Figure S3). Microscopy confirmed that the cultures treated with S-MGB-241 had fewer *Acanthamoeba* present. *Acanthamoeba* present at 24 hours exhibited morphological changes including rounding and less distinct membranes. These morphological changes were maintained 144 hours after removal of S-MGB-241, indicating that the effects of S-MGB-241 are long lived and potentially cidal (Figure S4).

These biological activity data identified S-MGB-241, **36**, as a compound worthy of further investigation due to its selective potency against *A. castellanii* and comparable activity to the clinically used compound, miltefosine.

Biophysical studies

Other S-MGBs have been shown to bind to double stranded DNA (dsDNA) using a variety of methods, including thermal shift analysis of genomic DNA (gDNA) and native mass spectrometry using short AT-rich dsDNA oligomers.^{11,15} Both techniques were employed on S-MGB-241, **36**, to provide evidence of DNA binding.

Native mass spectrometry was carried out using a short, self-complementary DNA oligo with an AT-rich binding site: 5'-CGCATATATGCG-3' (Figure 3). The choice of dsDNA oligo, containing an AT-rich binding site, is based on our previous studies on S-MGBs showing that this oligo is good for evaluating their binding due to similar binding preferences to distamycin, the template




Figure 2. Synthetic route used to generate final S-MGB compounds **27–38**. Reagents and conditions: (a) HBTU, amine **9**, **10** or **11**, DMF. (b) (i) Pd/C, MeOH, 2 h. (c) HBTU, DMF. (d) (i) **20**, HCl (gas), EtOH, -60°C , 1.5 h, RT, 14 h. (ii) NH_3 , MeOH, 55°C , 6 h. (e) Pd/C, MeOH, amine **18**, **19** or **21**, 4 h. (f) HBTU, with acid **25**, or **26** when $R^2 = \text{A, B}$ or **D**, DMF, RT, overnight. (g) **27–32**, LiOH, H_2O , MeOH, $80\text{--}100^{\circ}\text{C}$.

from which S-MGBs are derived. Analysis of the native MS spectrum of dsDNA oligo 5'-CGCATATATGCG-3' in the presence of S-MGB-241, **36**, provides conclusive evidence that the S-MGB binds as a dimer [DS+2 M], in charge states 5- and 4- (Figure 3). No evidence of S-MGB-241, **36**, bound as a monomer [DS+1 M] was observed. There is also a strong m/z peak corresponding to the free dsDNA

oligo in the S-MGB-241-treated experiment. This is perhaps indicative of weaker binding compared to S-MGBs that have been explored in other studies, for which free dsDNA is not strongly observed.^{11,15}

The DNA thermal shift of S-MGB-241, **36**, using a model gDNA extracted from salmon, showed a statistically significant, but

Table 1. Activity profiles of 12 tested S-MGBs against *Acanthamoeba castellanii*, *Trypanosoma brucei*, *Staphylococcus aureus* and *Escherichia coli*.

Cmp N ^o	S-MGB-ID	R ¹	R ²	Activity		
				<i>A. castellanii</i> IC ₅₀ (μM) ^a	<i>T. b. brucei</i> MIC (μM) ^b	<i>E. coli</i> or <i>S. aureus</i> MIC (μM) ^b
36	241			6.6 ±0.40	100	>100
31	227			18.0 ±3.2	3.12	>100
38	237			45.8 ±1.2	100	>100
27	240			69.9 ±1.4	100	>100
32	233			87.4 ±3.8	25	>100
35	236			>100	100	>100
30	238			>100	100	>100
37	228			>100	100	>100
29	231			>100	100	>100
28	229			>100	12.5	>100
34	230			>100	100	>100
33	242			>100	25	>100

S-MGBs are ordered by activity against *A. castellanii*.

^aHalf maximal inhibitory concentration (IC₅₀), and SE are shown where <100 μM. The positive control compound, miltefosine, has an IC₅₀ of 5.6 μM against *A. castellanii*.

^bMICs defined as concentration to inhibit 80% of growth.




Figure 3. (a) Characterization of S-MGB-241, **36**, binding to double stranded DNA as a dimer by nMS. nESI-MS of DNA sequence 5'-CGCATATATGCG-3' (9 μ M DNA, 100 μ M KCl, 1% DMSO) sprayed from ammonium acetate (150 mM, pH 7) in the absence (i) or presence (ii) of 100 μ M S-MGB. (i) Single stranded DNA (denoted [SS]) is present in charge states 4- and 3-, and double stranded DNA (denoted [DS]) is present in charge states 5- and 4-. (ii) [SS] is present in charge states 3- and 4-. [DS] is present in charge state 4-. Each bound [DS] molecule is seen to bind 2xS-MGB-241 molecules (denoted [DS+2M]) and is present in charge states 5- and 4-. (b) and (c) Thermal melt analysis data of S-MGB-241, **36** bound to gDNA, including exemplar melt curve from one experimental repeat, fitted with a Boltzmann distribution. Additional details of native mass spectrometry and thermal melt analysis are presented in the Supplementary Information (Tables S1–S4). This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.

small increase in melting temperature, $\Delta T_m = 1.3 \pm 0.1^\circ\text{C}$ (SE; Figure 2b). Under these experimental conditions we have observed potent (<1 μ M) antibacterial S-MGBs to have ΔT_m values in the range of 1 to >15°C, and therefore S-MGB-241, **36**, would be considered a weakly binding compound.^{11,15}

Conclusion

Herein 12 previously unpublished S-MGBs have been synthesized and evaluated for biological activity against *A. castellanii*, *T. b. brucei*, *S. aureus* and *E. coli*. S-MGB-241, **36**, was identified as a selective anti-*Acanthamoeba* agent with an IC_{50} of 6.6 μ M against *A. castellanii*, comparable in potency to the clinically used miltefosine (5.8 μ M).

Although it has been used clinically as an adjunct therapy for AK, miltefosine, is liable to induce toxic side effects due to its membrane permeabilizing mechanism of action. Indeed, none of the existing clinical options are particularly effective, and most suffer from adverse side effects. Therefore, S-MGB-241, **36**, is a valuable 'hit' compound for future optimization.

Both a thermal shift assay and native mass spectrometry confirmed that S-MGB-241, **36**, binds to dsDNA, albeit weakly compared to S-MGBs from other anti-infective drug discovery programmes. For example, MGB-BP-3 has sub-micromolar potency against various Gram-positive bacteria and has $\Delta T_m > 15^\circ\text{C}$ in the same DNA thermal shift assay, compared to a $\Delta T_m = 1^\circ\text{C}$ for S-MGB-241, **36**.¹⁵ Similarly, S-MGB-364, a compound with an MIC_{99} of 1.56 μ M against *Mycobacterium tuberculosis* (H37Rv-GFP), has a $\Delta T_m = 16^\circ\text{C}$.^{11,22} In line with their stronger DNA binding, both MGB-BP-3 and S-MGB-364 show limited

evidence of unbound dsDNA oligo in similar native mass spectrometry experiments as carried out herein with S-MGB-241, **36**.^{11,15}

The potency of MGB-BP-3 was also measured against *A. castellanii* (Figure S5), which had an IC_{50} of ~ 50 μ M, about 8-fold higher than S-MGB-241. This further suggests that DNA binding alone does not account for potency. Indeed, potency for antimicrobials that target an intracellular mechanism is governed by both target engagement and intracellular accumulation. Therefore, we suggest that S-MGB-241's weak DNA binding is compensated by a greater intracellular accumulation to account for a higher potency against *A. castellanii* compared to MGB-BP-3. Improvements in potency of S-MGB-241 could thus be achieved by enhancing its DNA binding without compromising its favourable intracellular accumulation. This is consistent with findings from across our S-MGB drug discovery platform, where selectivity appears to be driven by differential accumulation in pathogen or mammalian cells rather than through differences in target engagement, although DNA binding is a minimal characteristic for potency.²¹

The shorter structure of S-MGB-241, **36**, in comparison to some other S-MGBs is the likely origin of its comparatively weaker DNA binding. Indeed, we have previously observed a series of 'truncated' S-MGBs with selective anti-parasitic properties, lacked potent antibacterial activity.¹⁸ Both studies suggest that shorter S-MGBs possess weaker binding, but may also contribute to selective activity towards parasites. Therefore, future optimization strategies for *A. castellanii* potency could seek to increase DNA binding without altering the length of the S-MGB.

In conclusion, S-MGB-241, **36**, has been identified as a zwitterionic S-MGB that is selectively active against *A. castellanii*, and

with comparable potency to miltefosine, which is used clinically in the treatment of *Acanthamoeba* infections. The zwitterionic structure of S-MGB-241, **36**, may pose an issue for downstream drug development efforts; however, this 'hit' compound provides a starting point from which to optimize the structure, with a focus on improving DNA binding, to increase potency.

Funding

A.G.C.S. was funded by a Scholarship from Consejo Nacional de Humanidades, Ciencias y Tecnologías (CONAHCYT). This work was in part supported by an EPSRC DTP award to the University of Strathclyde, EP/T517938/1 (2432483). For the purpose of open access, the author(s) has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript (AAM) version arising from this submission.

Transparency declarations

The authors declare the following competing financial interest(s): C.J.S. and F.J.S. are part of revenue sharing agreements with their University relating to the Strathclyde Minor Groove Binder project. Additionally, C.J.S. and F.J.S. have financial interests through shares in the company, Rostra Therapeutics. All other authors: none to declare.

Author contributions

F.J.S. and M.P. carried out the chemical synthesis. A.G.C.S., Y.B., L.M., K.E. and F.J.S. contributed to the various susceptibility and cytotoxicity testing. L.M.C.M. performed the native mass spectrometry experiments and the DNA thermal melt experiments. Further intellectual contributions to the project and its management were made by L.M.C.M., A.G.C.S., M.P., Y.B., L.M., K.E., L.Y., R.B., C.J.S., C.W.R. and F.J.S. All authors contributed to writing their respective parts of the paper. Executive manuscript preparation, drafting and management were carried out by L.M.C.M., C.W.R., C.J.S., L.Y., R.B. and F.J.S.

Supplementary data

Figures **S1 to S5** and Tables **S1 to S4** are available as [Supplementary data](#) at JAC Online.

References

- Wang Y, Jiang L, Zhao Y et al. Biological characteristics and pathogenicity of *Acanthamoeba*. *Front Microbiol* 2023; **14**: 1147077. <https://doi.org/10.3389/fmicb.2023.1147077>
- Ahmed U, Anwar A, Ong S-K et al. Applications of medicinal chemistry for drug discovery against *Acanthamoeba* infections. *Med Res Rev* 2022; **42**: 462–512. <https://doi.org/10.1002/med.21851>
- Azzopardi M, Chong YJ, Ng B et al. Diagnosis of *Acanthamoeba* keratitis: past, present and future. *Diagnostics* 2023; **13**: 2655. <https://doi.org/10.3390/diagnostics13162655>
- Zhang H, Cheng X. Various brain-eating amoebae: the protozoa, the pathogenesis, and the disease. *Front Med* 2021; **15**: 842–66. <https://doi.org/10.1007/s11684-021-0865-2>
- Elsheikha HM, Siddiqui R, Khan NA. Drug discovery against *Acanthamoeba* infections: present knowledge and unmet needs. *Pathogens* 2020; **9**: 405. <https://doi.org/10.3390/pathogens9050405>
- Taravaud A, Fechtali-Moute Z, Loiseau PM et al. Drugs used for the treatment of cerebral and disseminated infections caused by free-living amoebae. *Clin Transl Sci* 2021; **14**: 791–805. <https://doi.org/10.1111/cts.12955>
- Juárez MM, Tártara LI, Cid AG et al. *Acanthamoeba* in the eye, can the parasite hide even more? Latest developments on the disease. *Cont Lens Anterior Eye* 2017; **41**: 245–51. <https://doi.org/10.1016/j.clae.2017.12.017>
- Dart JKG, Saw VPJ, Kilvington S. *Acanthamoeba* keratitis: diagnosis and treatment update. *Am J Ophthalmol* 2009; **148**: 487–99. <https://doi.org/10.1016/j.ajo.2009.06.009>
- Thulasi P, Saeed HN, Rapuano CJ et al. Oral miltefosine as salvage therapy for refractory *Acanthamoeba* keratitis. *Am J Ophthalmol* 2021; **223**: 75–82. <https://doi.org/10.1016/j.ajo.2020.09.048>
- Kieswetter NS, Ozturk M, Hlaka L et al. Intranasally administered S-MGB-364 displays antitubercular activity and modulates the host immune response to *Mycobacterium tuberculosis* infection. *J Antimicrob Chemother* 2022; **77**: 1061–71. <https://doi.org/10.1093/jac/dkac001>
- Giordani F, Khalaf AI, Gillingwater K et al. Novel minor groove binders cure animal African trypanosomiasis in an in vivo mouse model. *J Med Chem* 2019; **62**: 3021–35. <https://doi.org/10.1021/acs.jmedchem.8b01847>
- Scott FJ, Nichol RJO, Khalaf AI et al. An evaluation of minor groove binders as anti-fungal and anti-mycobacterial therapeutics. *Eur J Med Chem* 2017; **136**: 561–72. <https://doi.org/10.1016/j.ejmech.2017.05.039>
- Khalaf AI, Anthony N, Breen D et al. Amide isosteres in structure-activity studies of antibacterial minor groove binders. *Eur J Med Chem* 2011; **46**: 5343–55. <https://doi.org/10.1016/j.ejmech.2011.08.035>
- Hind C, Clifford M, Woolley C et al. Insights into the spectrum of activity and mechanism of action of MGB-BP-3. *ACS Infect Dis* 2022; **8**: 2552–63. <https://doi.org/10.1021/acscinfdis.2c00445>
- Suckling CJ, Hunter IS, Scott FJ. Multitargeted anti-infective drugs: resilience to resistance in the antimicrobial resistance era. *Future Drug Discovery* 2022; **4**: FDD73. <https://doi.org/10.4155/fdd-2022-0001>
- Kerr L, Browning DF, Lemonidis K et al. Novel antibiotic mode of action by repression of promoter isomerisation. *BioRxiv* 2021: 12.31.424950. <https://doi.org/10.1101/2020.12.31.424950>
- Alniss HY, Khan NA, Boghossian A et al. Synthesis and evaluation of novel DNA minor groove binders as anti-amoebic agents. *Antibiotics* 2022; **11**: 935. <https://doi.org/10.3390/antibiotics11070935>
- Brooke DP, McGee LMC, Giordani F et al. Truncated S-MGBs: towards a parasite-specific and low aggregation chemotype. *RSC Med Chem* 2021; **12**: 1391–401. <https://doi.org/10.1039/d1md00110h>
- McBride J, Ingram PR, Henriquez FL et al. Development of colorimetric microtiter plate assay for assessment of antimicrobials against *acanthamoeba*. *J Clin Microbiol* 2005; **43**: 629–34. <https://doi.org/10.1128/JCM.43.2.629-634.2005>
- Khalaf AI, Waigh RD, Drummond AJ et al. Distamycin analogues with enhanced lipophilicity: synthesis and antimicrobial activity. *J Med Chem* 2004; **47**: 2133–56. <https://doi.org/10.1021/jm031089x>
- Tentellino C, Tipping WJ, McGee LMC et al. Ratiometric imaging of minor groove binders in mammalian cells using Raman microscopy. *RSC Chem Bio* 2022; **3**: 1403–15. <https://doi.org/10.1039/d2cb00159d>
- Hlaka L, Rosslee M-J, Ozturk M et al. Evaluation of minor groove binders (MGBs) as novel anti-mycobacterial agents and the effect of using non-ionic surfactant vesicles as a delivery system to improve their efficacy. *J Antimicrob Chemother* 2017; **72**: 3334–41. <https://doi.org/10.1093/jac/dkx326>